Receptor activator of the nuclear factor kappa B ligand (RANKL) has been recently identified as a target of interest in the tumor microenvironment (TME), specifically in facilitating an immunosuppressive environment and subsequent resistance to immunotherapy. This evidence concerns the gene TNFSF11 and neoplasm.